Growth Hormone in Obese Cases With Covid-19

C

ClinAmygate

Status and phase

Withdrawn
Phase 4

Conditions

Covid19

Treatments

Drug: Growth Hormone
Drug: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT04532554
PR0015

Details and patient eligibility

About

The use of growth hormone in obese cases with COVID-19 may help them to recover earlier.

Full description

It is well known that lymphoid organs such the thymus, the spleen and peripheral blood produce growth hormone (GH) and GH receptor is expressed on different subpopulations of lymphocytes. Many in vitro and in animal studies demonstrate an important role of GH in immunoregulation. GH stimulates T and B cells proliferation and immunoglobulin synthesis, enhances the maturation of myeloid progenitor cells and is also able to modulate cytokine response. The use of growth hormone in obese cases with COVID-19 may help them to recover earlier.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Obese with BMI > 30

Exclusion criteria

History of hypersensitivity to GH

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

0 participants in 2 patient groups, including a placebo group

Growth hormone
Experimental group
Description:
Recombinant GH will be used for those patients
Treatment:
Drug: Growth Hormone
Placebo
Placebo Comparator group
Description:
Saline will be used
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems